Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Center Experience.

被引：0
|
作者：
Fraenkel, M. [1 ]
Barak, D. [1 ]
Mueller-Brand, J. [2 ]
Krausz, Y. [1 ]
Glaser, B. [1 ]
Salmon, A. [1 ]
Gross, D. J. [1 ]
机构：
[1] Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel
[2] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
ENDOCRINE REVIEWS | 2010年 / 31卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] THE NURSES ROLE IN PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) WITH LUTATHERA
    Longing, Anne
    Boswell, Abigail
    Kennedy, Matthew
    ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [22] Peptide receptor radionuclide therapy in patients with pulmonary neuroendocrine tumors: our experience.
    Minutoli, F.
    Cardile, D.
    Cucinotta, M.
    Quartuccio, N.
    Gangemi, V.
    Sindoni, A.
    Baldari, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S531 - S531
  • [23] Initial Experience With Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors (NETS) at a Tertiary Care United States Center
    Heckert, Jason
    Botterbusch, Samuel
    Kipnis, Sarit
    Bennet, Bonita
    Creamer, Caroline
    Alderson, Alice
    Eads, Jennifer
    Soulen, Michael
    Pryma, Daniel
    Mankoff, David
    Metz, David
    Katona, Bryson
    PANCREAS, 2020, 49 (03) : 470 - 471
  • [24] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs): A United States Experience
    Katona, Bryson
    Riff, Brian
    Soulen, Michael
    Pryma, Daniel
    Bennett, Bonita
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina
    Metz, David
    PANCREAS, 2017, 46 (03) : 439 - 439
  • [25] Efficacy and safety of peptide receptor radionuclide therapy (PRRT) in patients with chronic kidney disease (CKD)
    Alsadik, S. R.
    Gnanasegaran, G.
    Chen, L.
    Toumpanakis, C.
    Caplin, M.
    Navalkissoor, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 170 - 170
  • [26] Peptide receptor radionuclide therapy (PRRT) - current state and innovative developments
    Baum, R. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 297 - 297
  • [27] Peptide receptor radionuclide therapy (PRRT) using somatostatin analogs.
    Capello, A
    Krenning, EP
    Bernard, HF
    Breeman, WA
    Van Den Aardweg, G
    De Jong, M
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 125P - 125P
  • [28] Differences in pretherapeutic and therapeutic biodistributions in peptide receptor radionuclide therapy (PRRT)
    Kletting, P.
    Mueller, B.
    Schmaljohann, J.
    Behrendt, F. F.
    Reske, S. N.
    Mottaghy, F. M.
    Glatting, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S351 - S351
  • [29] Pretherapy Prediction of Nephrotoxicity After Peptide Radionuclide Receptor Therapy (PRRT)
    DeNardo, Gerald L.
    Macey, Daniel J.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2010, 25 (05) : 507 - 509
  • [30] INITIAL EXPERIENCE WITH PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) FOR THE TREATMENT OF NEUROENDOCRINE TUMOR (NET) AT A TERTIARY CARE UNITED STATES CENTER.
    Heckert, Jason
    Eads, Jennifer
    Soulen, Michael C.
    Pryma, Daniel
    Mankoff, David
    Metz, David C.
    Katona, Bryson W.
    GASTROENTEROLOGY, 2019, 156 (06) : S370 - S370
12345